8-K: Acura amends loan schedule, total debt reaches $10.89M with new 2026 loans

Acura Pharmaceuticals amended the loan schedule to its secured promissory note with Abuse Deterrent Pharma, originally dated November 10, 2022 for $2,319,279. The amendment adds 63 additional loans, bringing the aggregated principal to $10,894,279 as of July 17, 2026. The new schedule includes 13 loans in 2026 totaling $1,500,000, with the final loan of $200,000 dated July 17, 2026. This filing discloses the continued reliance on related-party debt financing to fund operations.

Acura Pharmaceuticals amended the loan schedule to its secured promissory note with Abuse Deterrent Pharma, originally dated November 10, 2022 for $2,319,279. The amendment adds 63 additional loans, b